DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Natacyn (Natamycin Ophthalmic) - Summary



(natamycin ophthalmic suspension)

NATACYN® (natamycin ophthalmic suspension) 5% is a sterile, antifungal drug for topical ophthalmic administration.

NATACYN (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.

See all Natacyn indications & dosage >>


Published Studies Related to Natacyn (Natamycin Ophthalmic)

Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. [2014]
MIC values from 221 patients with monocular fungal keratitis... CONCLUSIONS: Decreased susceptibility to natamycin was associated with increased

The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. [2013]
filamentous fungal keratitis... CONCLUSIONS: Natamycin treatment was associated with significantly better

Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. [2011.07]
BACKGROUND: To evaluate the efficacy of topical 1% voriconazole versus 5% natamycin in treatment of fungal corneal ulcers. DESIGN: A prospective, randomized pilot study in a tertiary care hospital. PARTICIPANTS: Thirty patients of microbiologically proven fungal keratitis divided randomly in two groups of 15 patients each... CONCLUSION: Topical 1% voriconazole was found to be safe and effective drug in primary management of fungal keratitis, its efficacy matching conventional natamycin. There was no added advantage of using topical 1% voriconazole over topical natamycin as primary treatment in fungal keratitis. (c) 2011 The Authors. Clinical and Experimental Ophthalmology (c) 2011 Royal Australian and New Zealand College of Ophthalmologists.

Comparison of natamycin and voriconazole for the treatment of fungal keratitis. [2010.06]
OBJECTIVE: To conduct a therapeutic exploratory clinical trial comparing clinical outcomes of treatment with topical natamycin vs topical voriconazole for fungal keratitis... CONCLUSIONS: Overall, there were no significant differences in visual acuity, scar size, and perforations between voriconazole- and natamycin-treated patients. There was a trend toward scraping being associated with worse outcomes. Application to Clinical Practice The benefit seen with voriconazole in the subgroup of patients with baseline visual acuity of 20/40 to 20/400 needs to be validated in a confirmatory clinical trial. Trial Registration clinicaltrials.gov Identifier: NCT00557362.

Comparison of natamycin and voriconazole for the treatment of fungal keratitis. [2010]
keratitis... CONCLUSIONS: Overall, there were no significant differences in visual acuity,

more studies >>

Clinical Trials Related to Natacyn (Natamycin Ophthalmic)

Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer [Completed]
We evaluated whether voriconazole is a superior treatment to natamycin for filamentous fungal keratitis in a randomized, masked, controlled trial. This is a therapeutic exploratory study to investigate the safety and feasibility of conducting a larger study and to generate preliminary data.

Mycotic Ulcer Treatment Trial I [Completed]

Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis [Recruiting]
The study is a randomised control trial to assess the visual and clinical outcomes of collagen cross linking in fungal keratitis. Fungal keratitis is a major cause of corneal blindness in India and the therapeutic options available are minimal to handle the advanced complications and sequalae caused by the disease. The antimicrobial and tissue remodeling role of corneal cross linking was demonstrated by several studies earlier,we anted to specifically assess the role of corneal cross linking in non resolving fungal keratitis in prevention of perforation and enhancement of healing process.

A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine [Terminated]
The purpose of this study is to determine the effectiveness of 1. 25% povidone-iodine ophthalmic solution for the treatment of small to medium sized fungal corneal ulcers compared with an antifungal antibiotic.

Mycotic Ulcer Treatment Trial II [Recruiting]
The purpose of this study is to determine if the addition of oral voriconazole to topical treatment regimens results in lower rates of perforation in severe fungal corneal ulcers.

more trials >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017